An animal study has identified a potential new therapeutic option for treating cardiac fibrosis: L-carnitine supplementation. Could L-carnitine prevent the development of heart failure?
Researchers (Y Omori, T Ohtani, et al), at the Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan, developed an animal study to analyze potential new treatments for heart failure—specifically heart failure with preserved ejection fraction (HFpEF) in hypertensive heart disease.
Hypertensive heart disease is caused by hypertension, or high blood pressure. Hypertensive heart disease with heart failure is a serious condition, which can lead to ischemic heart disease and heart attacks. Heart disease is leading cause of death worldwide, according to the World Health Organization.
The researchers were aware that prognosis of heart failure with preserved ejection fraction is poor. They knew that hypertension causes decreased free-carnitine levels in the heart. Would L-carnitine supplements have an effect?
Carnitine is a non-essential amino acid, synthesized in the human body from the amino acids lysine and methionine. Carnitine is also found in food, especially red meat and dairy products. L-carnitine is simply the biologically-active form of carnitine.
Carnitine has a substantial antioxidant effect, which greatly benefits health by preventing free radical damage. The researchers hoped that the carnitine supplements would also combat hypertension.
L-carnitine treatment and heart failure study
Rats were given a high-salt diet, which models hypertensive heart failure. Their free carnitine levels were measured, and were found to be low in the left ventricle of the heart. The rats were then given L-carnitine supplements.
This L-carnitine treatment had a significant impact. It restored the levels of carnitine in the chambers of the heart, and even reversed fibrosis. Cardiac fibrosis is a thickening of the heart valves, which is often found in heart failure.
The affect L-carnitine has on reversing, or thinning, the level of cardiac fibrosis means that L-carnitine could become a therapeutic option for treating hypertensive heart disease in the future.